Facilitated By

San Antonio Medical Foundation

Development of the New Synthetic Triterpenoid CDDO-2P-Im for Chemoprevention of the ARDS of COVID-19

Texas Biomedical Research Institute

 

As one of the world’s leading independent biomedical research institutions, Texas Biomedical Research Institute is dedicated to advancing the health of our global community through innovative biomedical research.

Principal Investigator(s)
Torrelles, Jordi B
Collaborating Institutions
Triterpenoid Therapeutics Inc
Funded by
National Institutes of Health
Research Start Date
Status
Active

For this proposal, we will be responsible for the experiments involving infection of K18 hACE2 mice with SARS-CoV-2 USA-WA1/2020 strain and assess the effectivity of a drug compound provided by the partnering company.

Collaborative Project
Drug Discovery
Infectious Disease